DSM-5 Anksiyöz Distres Değerlendirme Ölçeği Türkçe Formunun majör depresif bozukluk için geçerlilik ve güvenilirlik çalışması

Amaç: Bu çalışmanın amacı DSM-5 Anksiyöz Distres Değerlendirme Ölçeğinin (ADDÖ) (DSM-5 Anxious Distress Specifier Interview) Türkçe formunun majör depresif bozuklukta geçerlilik ve güvenilirliğini incelemektir. Yöntem:Çalışmaya Yozgat Şehir Hastanesi Psikiyatri Polikliniği’ne başvuran ve majör depresif bozukluk ölçütlerini karşılayan 40 hasta ve 72 sağlıklı kontrol alınmıştır. Tüm katılımcılara DSM-5 Bozuklukları için Yapılandırılmış Klinik Görüşme- Klinisyen Versiyonu (SCID-5-CV), Anksiyöz Distres Değerlendirme Ölçeği (ADDÖ), Hamilton Depresyon Derecelendirme Ölçeği 17 maddelik form (HDDÖ-17), Hamilton Anksiyete Değerlendirme Ölçeği (HADÖ) uygulanmıştır. Güvenilirlik analizlerinde iç tutarlılık katsayısı hesaplanmış ve madde-toplam puan korelasyon analizi yapılmıştır. Geçerlilik analizinde faktör geçerliliği için açıklayıcı faktör analizi, benzer ölçek geçerliliği için ölçek korelasyon ve parsiyel korelasyon analizleri yapılmıştır. ADDÖ’nün hasta ve kontrol grubunu ayırt ediciliğini göstermek amacıyla Mann-Whitney U testi ve ROC analizi yapılmıştır. Sonuçlar: Geçerlilik analizi sonucunda tek faktörlü çözüm elde edilmiştir. Madde faktör yüklerinin 0.646-0.817 arasında yer aldığı, birleşim ve ayırt edici geçerliliğininsağlandığı görülmüştür. İç tutarlılık katsayısının 0.764, madde-toplam puan korelasyon katsayılarının 0.540-0.654 arasında olduğu bulunmuştur. ROC analizinde eğri altında kalan alan 0.98 bulunmuştur. Hastaların ADDÖ toplam puanı kontrollerden anlamlı olarak yüksek bulunmuştur (p

Reliability and validity of the Turkish Version of DSM-5 Anxious Distress Rating Scale for major depressive disorder

Objective: The aim of the present study was to investigate the reliability and validity of Turkish Form of DSM-5 Anxious Distress Specifier Interview for major depressive disorder. Methods: The study was conducted in Psychiatry Clinic of Yozgat City Hospital. The participants were 40 outpatients met the diagnosis of major depressive disorder and 72 healthy controls. All participants were evaluated with The Structured Clinical Interview for DSM-5 Disorders-Clininican Version (SCID-5-CV), Anxious Distress Rating Scale (ADRS), Hamilton Depression Rating Scale 17 item form (HAMD-17) and Hamilton Anxiety Rating Scale (HAMA). Internal consistency coefficient was calculated and item-total score correlation analysis was made for evaluating reliability. Exploratory factor analysis for factor validity and Pearson’s correlation and partial correlation analyses for discriminant-convergent validity were conducted. Mann-Whitney U test and ROC analysis were performed so as to show how much ADRS differentiates the patient group and the control group. Results: As a result of the validity analysis, it was observed that the singlefactor design of the scale was confirmed, item factor loads were between 0.664-0.817, and discriminant-converg validity was provided. Internal consistency coefficient was 0.764, and the item-total score correlation coefficients ranged from 0.540 to 0.655. In ROC analysis area under the curve was 0.98. ADRS total score of the patients was found to be significantly higher than the controls (p

PDF

___

1. Fava M, Rankin MA, Wright EC, Alpert JE, Nierenberg AA, Pava J, et al. Anxiety disorders in major depression. Compr Psychiatry 2000; 41(Suppl.2):97-102.

2. Zimmerman M, Chelminski I, McDermut W. Major depressive disorder and axis I diagnostic comorbidity. J Clin Psychiatry 2002; 63(Suppl.3):187-193.

3. Gorman JM. Comorbid depression and anxiety spectrum disorders. Depress Anxiety. 1996; 4(Suppl.4):160-168.

4. Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008; 165(Suppl.3):342-351.

5. Lin C-H, Wang F-C, Lin S-C, Chen C-C, Huang C-J. A comparison of inpatients with anxious depression to those with nonanxious depression. Psychiatry Res 2014; 220(Suppl.3):855-860.

6. Chan HN, Rush AJ, Nierenberg AA, Trivedi M, Wisniewski SR, Balasubramani GK, et al. Correlates and outcomes of depressed out-patients with greater and fewer anxious symptoms: a CO-MED report. Int J Neuropsychopharmacol. 2012; 15(Suppl.10):1387-1399.

7. Gaspersz R, Lamers F, Kent JM, Beekman ATF, Smit JH, van Hemert AM, et al. Anxious distress predicts subsequent treatment outcome and side effects in depressed patients starting antidepressant treatment. J Psychiatr Res 2017; 84:41-48.

8. Fava M, Alpert JE, Carmin CN, Wisniewski SR, Trivedi MH, Biggs MM, et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med 2004; 34(Suppl.7):1299-1308.

9. Walters K, Buszewicz M, Weich S, King M. Mixed anxiety and depressive disorder outcomes: prospective cohort study in primary care. Br J Psychiatry J Ment Sci. 2011; 198(6):472-478.

10. Türkçapar H. Anksiyete bozukluğu ve depresyonun tanısal ilişkileri. Klin Psikiyatri 2004; 4:12-16.

11. Organization WH. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Vol. 2. World Health Organization, 1993.

12. Andrade LH, Wang Y-P. How global epidemiological evidence can inform the revision of ICD-10 classification of depression and anxiety disorders. World Psychiatry. 2012;5.

13. Stanković M, Grbeša G, Kostić J, Stanković S, Stevanović J. Changes Needed in the Classification of Anxiety Disorders in Childhood: Options for ICD-11. 2015; 143(Suppl.5-6):369-372.

14. Weisberg RB, Maki KM, Culpepper L, Keller MB. Is anyone really M.A.D.? The occurrence and course of mixed anxiety-depressive disorder in a sample of primary care patients. J Nerv Ment Dis 2005; 193(Suppl.4): 223-230.

15. Means-Christensen AJ, Sherbourne CD, Roy-Byrne PP, Schulman MC, Wu J, Dugdale DC, et al. In search of mixed anxiety-depressive disorder: a primary care study. Depress Anxiety 2006; 23(Suppl.4):183-189.

16. Baldwin DS, Florea I, Jacobsen PL, Zhong W, Nomikos GG. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. J Affect Disord 2016; 206:140-150.

17. Davis LL, Ota A, Perry P, Tsuneyoshi K, Weiller E, Baker RA. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study. Brain Behav 2016; 6(Suppl.10):e00520.

18. Thase ME, Demyttenaere K, Earley WR, Gustafsson U, Udd M, Eriksson H. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression. Depress Anxiety 2012; 29(Suppl.7):574-586.

19. Möller H-J, Bandelow B, Volz H-P, Barnikol UB, Seifritz E, Kasper S. The relevance of “mixed anxiety and depression” as a diagnostic category in clinical practice. Eur Arch Psychiatry Clin Neurosci 2016; 266(Suppl.8): 725-736.

20. First MB. DSM-5 proposals for mood disorders: a cost benefit analysis. Curr Opin Psychiatry 2011; 24(Suppl.1): 1-9.

21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). Arlington: American Psychiatric Pub., 2013.

22. McIntyre RS, Woldeyohannes HO, Soczynska JK, Vinberg M, Cha DS, Lee Y, et al. The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive disorder: results from the International Mood Disorders Collaborative Project. Ther Adv Chronic Dis 2016; 7(Suppl.3):153-159.

23. Heij GJ, Penninx BWHJ, van Velzen LS, van Tol M-J, van der Wee NJA, Veltman DJ, et al. White matter architecture in major depression with anxious distress symptoms. Prog Neuropsychopharmacol Biol Psychiatry 2019; 94:109664.

24. Zimmerman M, Clark H, McGonigal P, Harris L, Holst CG, Martin J. Reliability and validity of the DSM-5 Anxious Distress Specifier Interview. Compr Psychiatry 2017; 76:11-17.

25. Elbir M, Topbas OA, Bayad S, Kocabas T, Topak OZ, Cetin S, ve ark. DSM-5 Bozuklukları için Yapılandırılmış Klinik Görüşmenin Klinisyen Versiyonunun Türkçeye uyarlanması ve güvenilirlik çalışması. Turk Psikiyatri Derg 2019; 30:51-56

26. Hamilton MA. Rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23(Suppl.1):56.

27. Akdemir A, Orsel SD, Dag I, Turkcapar MH, Iscan N, Ozbay H. Hamilton Depresyon Derecelendirme Ölçeği (HDDO)’nin geçerliği-güvenirliği ve klinikte kullanımı. Psikiyatri Psikol Psikofarmakol Derg 1996; 4:251-259.

28. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32(Suppl.1):50-55.

29. Yazıcı MK, Demir B, Tanrıverdi N, Karaağaoğlu E, Yolaç P. Hamilton Anksiyete Değerlendirme Ölçeği, değerlendiriciler arası güvenirlik ve geçerlik çalışması. Türk Psikiyatri Derg 1998; 9(Suppl.2):114-117.

30. Şencan H. Sosyal ve Davranışsal Ölçümlerde Güvenirlik ve Geçerlilik. Ankara: Seçkin Yayıncılık, 2005, s.37-77.

31. Cleary P, Guy W. Factor analysis of the Hamilton depression scale. Drugs Exp Clin Res 1977; 1(Suppl.1- 2):115-120.

32. Bech P, Gram LF, Dein E, Jacobsen O, Vitger J, Bolwig TG. Quantitative rating of depressive states. Acta Psychiatr Scand 1975; 51(Suppl.3):161-170.

33. Diedenhofen B, Musch J. cocor: a comprehensive solution for the statistical comparison of correlations. PloS One 2015; 10(Suppl.3):e0121945.

34. Tavsancıl E. Tutumların Ölçülmesi ve SPSS ile Veri Analizi. Beşinci baskı, Ankara: Nobel, 2014.

35. Zimmerman M, Chelminski I, Young D, Dalrymple K, Walsh E, Rosenstein L. A clinically useful self-report measure of the DSM-5 anxious distress specifier for major depressive disorder. J Clin Psychiatry 2014; 75(Suppl.6):601-607.

36. Çelikbaş Z, Batmaz S, Yüncü ÖA, Öztürk M, Akpınar Aslan E. Assessing depression with anxious distress and mixed features: The validity and reliability of the Turkish version of the clinically useful depression outcome scale (tur). J Clin Psychiatry 2020; 23(Suppl.1):43-55.

37. Rosellini AJ, Bourgeois ML, Correa J, Tung ES, Goncharenko S, Brown TA. Anxious distress in depressed out patients: Prevalence, comorbidity, and incremental validity. J Psychiatr Res 2018; 103:54-60.

38. Hasin DS, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry 2018; 75(Suppl.4):336-346.

39. Zimmerman M, Martin J, McGonigal P, Harris L, Kerr S, Balling C, et al. Validity of the DSM-5 anxious distress specifier for major depressive disorder. Depress Anxiety 2019; 36(1):31-38

40. Gorsuch RL. Exploratory factor analysis: its role in item analysis. J Pers Assess 1997; 68(Suppl.3):532-560.